AbbVie (NYSE:ABBV) Earns “Buy” Rating from Guggenheim

AbbVie (NYSE:ABBV)‘s stock had its “buy” rating reaffirmed by Guggenheim in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $288.00 target price on the stock. Guggenheim’s price target would indicate a potential upside of 4.26% from the stock’s current price.

Several other research analysts have also recently issued reports on ABBV. BNP Paribas Exane increased their price target on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Bank of America reissued a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Rothschild & Co Redburn increased their price target on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Leerink Partners increased their price target on AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Finally, BMO Capital Markets increased their price target on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $277.18.

AbbVie Trading Up 1.4%

NYSE:ABBV traded up $3.82 during mid-day trading on Friday, hitting $276.24. The stock had a trading volume of 4,297,337 shares, compared to its average volume of 6,418,720. The stock has a market capitalization of $488.06 billion, a price-to-earnings ratio of 78.03, a P/E/G ratio of 1.23 and a beta of 0.24. The company has a 50 day simple moving average of $259.06 and a 200-day simple moving average of $236.63. AbbVie has a 52 week low of $190.75 and a 52 week high of $277.60.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts anticipate that AbbVie will post 14.01 earnings per share for the current year.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by company insiders.

Institutional Investors Weigh In On AbbVie

Institutional investors and hedge funds have recently modified their holdings of the stock. Mirador Capital Partners LP boosted its stake in AbbVie by 3.0% in the 3rd quarter. Mirador Capital Partners LP now owns 70,834 shares of the company’s stock worth $18,529,000 after purchasing an additional 2,072 shares during the period. Sound Income Strategies LLC boosted its stake in AbbVie by 2.1% in the 3rd quarter. Sound Income Strategies LLC now owns 98,943 shares of the company’s stock worth $26,954,000 after purchasing an additional 2,040 shares during the period. GK Wealth Management LLC acquired a new position in AbbVie in the 3rd quarter worth approximately $87,000. Balefire LLC boosted its stake in AbbVie by 3.1% in the 3rd quarter. Balefire LLC now owns 4,121 shares of the company’s stock worth $1,078,000 after purchasing an additional 124 shares during the period. Finally, Riversedge Advisors LLC boosted its stake in AbbVie by 1.8% in the 3rd quarter. Riversedge Advisors LLC now owns 4,748 shares of the company’s stock worth $1,242,000 after purchasing an additional 82 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations strengthen AbbVie’s oncology pipeline. The FDA granted two Breakthrough Therapy designations to Temab-A (telisotuzumab adizutecan) for colorectal cancer and non-small cell lung cancer. The designation can accelerate development and regulatory review, although it does not guarantee approval or commercial success. AbbVie’s Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
• Positive Sentiment: Analysts raised their valuation targets. JPMorgan increased its target to $300 and maintained an overweight rating, while Cantor Fitzgerald lifted its target to $290 and Guggenheim reaffirmed a buy rating with a $288 target. These actions suggest analysts see additional upside from AbbVie’s growth products and pipeline. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Positive Sentiment: New products are more than offsetting Humira’s patent-loss decline. Humira revenue fell 35.9% to $756 million, but total quarterly revenue rose 10.2% to $16.99 billion. The performance indicates that immunology, neuroscience and other newer medicines are successfully replacing the former blockbuster. AbbVie Outgrew Humira’s Collapse
• Neutral Sentiment: Valuation and income appeal remain part of the debate. AbbVie’s dividend and defensive characteristics may attract income-focused investors, but the stock’s elevated valuation means continued earnings and pipeline execution are important to justify further gains. Treasury Bills or Dividend Stocks

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.